Tirzepatide 2.5mg for Weight Loss: What the Starter Dose Actually Does

Step 1: Why 2.5mg is the beginning, not the treatment

Tirzepatide works by activating two gut-hormone receptors (GIP and GLP-1) that slow gastric emptying, reduce appetite and help regulate blood sugar. That dual action is why the medicine is effective for weight management, and it is also why the first weeks require a gentler introduction. Starting at a full therapeutic strength would significantly increase the likelihood of nausea, vomiting and other gastrointestinal effects that tend to put people off treatment before it has a chance to work.

The 2.5mg dose carries a very low signal at both receptors. Most people experience little to no side effects at this stage. Some notice mild nausea, particularly in the first day or two after each injection, but it typically settles quickly. The point is to let your system adapt so that when the prescriber increases the dose (and eventually reaches a strength that produces meaningful weight loss) your body is already accustomed to the medicine's mechanism.

Think of it less as a dose and more as a four-week runway. The full Mounjaro overview explains how the KwikPen works and what to expect across the whole treatment journey, if that broader picture is useful at this stage.

Step 2: What actually happens during your first four weeks on tirzepatide

Your 2.5mg KwikPen contains four pre-set doses. You inject once a week, on the same day each week, rotating between the abdomen, thigh or upper arm. The pen is stored in the fridge between uses. Beyond the injection itself, the clinical work during these four weeks is largely observational, how is your appetite? Are you experiencing any GI effects? Is your weekly injection day manageable to stick to?

That last question is worth a brief practical note: pick a day that suits your routine. A lot of people land on a midweek day deliberately, so that any post-injection tiredness or nausea falls mid-week rather than cutting into a weekend. If your treatment starts at the beginning of the month (or after a bank holiday shifts your usual schedule) flag it with your prescriber so they can advise on timing. Small things, but they matter for consistency.

Towards the end of these four weeks, your prescriber will review how you have got on before deciding whether to increase to 5mg. That review is not a formality. The full tirzepatide dosing schedule covers what informs each step-up decision and what the eventual maintenance doses look like.

Step 3: Moving beyond 2.5mg (what the evidence says about where weight loss happens

The clinical trial that established tirzepatide's weight-loss profile) SURMOUNT-1, published in the New England Journal of Medicine, showed average weight reductions of around 20–21% of body weight at the 15mg maintenance dose over 72 weeks. Those results were achieved at the higher doses, after a gradual titration through 2.5mg, 5mg, 7.5mg and beyond. No one in that trial lost significant weight by staying at 2.5mg.

That is not a criticism of the starting dose, it is the design. NICE, in its guidance on tirzepatide (TA1026), recommends reviewing continuation after six months if less than 5% of body weight has been lost at the highest tolerated dose. The 2.5mg phase is not included in that calculation in isolation; it is the foundation on which the therapeutic doses are built.

If you want to understand what the step immediately after the starter dose looks like in practice, the page on tirzepatide 5mg for weight loss covers the first real dose increase in detail. For those further into the schedule, tirzepatide 7.5mg and tirzepatide 10mg are covered separately.

Step 4: Clinical assessment before you start, what eligibility looks like

Tirzepatide is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance. That is the licensed framework; suitability in practice also depends on your full medical history, current medicines and any contraindications a prescriber identifies.

The NHS medicines page for tirzepatide lists the conditions where it should not be used, including a personal or family history of medullary thyroid carcinoma or MEN2, and certain gastrointestinal conditions. Anyone who has had pancreatitis should discuss this with their prescriber before starting. It is also not recommended during pregnancy, while breastfeeding, or for those trying to conceive, and it is not licensed for under-18s.

Women taking the oral contraceptive pill should know that tirzepatide's effect on gastric emptying can reduce pill absorption. For the first four weeks of treatment, and for four weeks after each dose increase, an additional non-oral method of contraception is advisable, this is confirmed in NHS England's guidance on weight-management injections. Transdermal HRT may also be worth discussing with a GP if oral HRT is part of your current regimen.

Private treatment pricing for tirzepatide varies by dose and provider. A grounded overview of what the UK market looks like and what a legitimate price actually includes is on the Mounjaro price comparison page. When you are ready to take the next step, start your free consultation and a GPhC-registered prescriber will review your details the same day.